(NASDAQ: ENSC) Ensysce Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.84%.
Ensysce Biosciences's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ENSC's revenue for 2025 to be $7,965,545, with the lowest ENSC revenue forecast at $3,129,321, and the highest ENSC revenue forecast at $12,801,769. On average, 1 Wall Street analysts forecast ENSC's revenue for 2026 to be $23,706,980, with the lowest ENSC revenue forecast at $23,706,980, and the highest ENSC revenue forecast at $23,706,980.
In 2027, ENSC is forecast to generate $83,258,914 in revenue, with the lowest revenue forecast at $83,258,914 and the highest revenue forecast at $83,258,914.